CenExel Launches Pain Task Force to Standardize Non-Opioid Therapy Trials
Event summary
- CenExel Clinical Research formed a Pain Task Force on June 11, 2026, to address challenges in non-opioid pain therapy research.
- The task force unites pain researchers, investigators, and operational leaders across CenExel's nationwide network.
- Aims to standardize best practices, reduce variability, and improve data quality in pain clinical trials.
- CenExel has decades of experience in acute, chronic, neuropathic, and post-surgical pain studies.
The big picture
The formation of CenExel's Pain Task Force reflects the growing need for specialized approaches in pain research, an area plagued by high placebo response rates and patient variability. As the opioid crisis continues to drive demand for non-opioid alternatives, standardized trial methodologies could accelerate the development of new pain therapies. CenExel's move positions it as a potential leader in this niche, leveraging its extensive network and experience to attract sponsors seeking reliable clinical data.
What we're watching
- Execution Risk
- How the Pain Task Force's standardization efforts will impact the success rate of non-opioid pain therapy trials.
- Industry Trends
- Whether CenExel's approach will set a new standard for pain research in the clinical trials space.
- Market Dynamics
- The pace at which non-opioid pain therapies advance through clinical development with improved trial methodologies.
Related topics